These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 20978365)

  • 21. Comparison of (68)Ga-DOTATATE and (18)F-fluorodeoxyglucose PET/CT in the detection of recurrent medullary thyroid carcinoma.
    Conry BG; Papathanasiou ND; Prakash V; Kayani I; Caplin M; Mahmood S; Bomanji JB
    Eur J Nucl Med Mol Imaging; 2010 Jan; 37(1):49-57. PubMed ID: 19662413
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of FDG-PET computed tomography for surgery of recurrent or persistent differentiated thyroid carcinoma.
    Weber T; Ohlhauser D; Hillenbrand A; Henne-Bruns D; Reske SN; Luster M
    Horm Metab Res; 2012 Nov; 44(12):904-8. PubMed ID: 22791600
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The value of fluorine-18 fluorodeoxyglucose PET in patients with medullary thyroid cancer.
    Brandt-Mainz K; Müller SP; Görges R; Saller B; Bockisch A
    Eur J Nucl Med; 2000 May; 27(5):490-6. PubMed ID: 10853802
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Diagnostic values of ultrasound and (18)F-fluoro-2-deoxy-D-glucose-positron emission tomography/computerized tomography for patients with suspected thyroid carcinoma and lymph node metastasis].
    Lai XJ; Zhang B; Jiang YX; Dai Q; Zhao RN
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2013 Aug; 35(4):393-7. PubMed ID: 23987485
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sensitivity and prognostic value of positron emission tomography with F-18-fluorodeoxyglucose and sensitivity of immunoscintigraphy in patients with medullary thyroid carcinoma treated with anticarcinoembryonic antigen-targeted radioimmunotherapy.
    Oudoux A; Salaun PY; Bournaud C; Campion L; Ansquer C; Rousseau C; Bardet S; Borson-Chazot F; Vuillez JP; Murat A; Mirallié E; Barbet J; Goldenberg DM; Chatal JF; Kraeber-Bodéré F
    J Clin Endocrinol Metab; 2007 Dec; 92(12):4590-7. PubMed ID: 17878252
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Diagnostic impact of PET with 18F-FDG, 18F-DOPA and 3-O-methyl-6-[18F]fluoro-DOPA in recurrent or metastatic medullary thyroid carcinoma.
    Beuthien-Baumann B; Strumpf A; Zessin J; Bredow J; Kotzerke J
    Eur J Nucl Med Mol Imaging; 2007 Oct; 34(10):1604-9. PubMed ID: 17435996
    [TBL] [Abstract][Full Text] [Related]  

  • 27. THE COMBINED USE OF CALCITONIN DOUBLING TIME AND
    Yang JH; Camacho CP; Lindsey SC; Valente FOF; Andreoni DM; Yamaga LY; Wagner J; Biscolla RPM; Maciel RMB
    Endocr Pract; 2017 Aug; 23(8):942-948. PubMed ID: 28614009
    [TBL] [Abstract][Full Text] [Related]  

  • 28. 18F-dihydroxyphenylalanine PET in patients with biochemical evidence of medullary thyroid cancer: relation to tumor differentiation.
    Koopmans KP; de Groot JW; Plukker JT; de Vries EG; Kema IP; Sluiter WJ; Jager PL; Links TP
    J Nucl Med; 2008 Apr; 49(4):524-31. PubMed ID: 18375923
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Complementary roles of 18F-DOPA PET/CT and 18F-FDG PET/CT in medullary thyroid cancer.
    Kauhanen S; Schalin-Jäntti C; Seppänen M; Kajander S; Virtanen S; Schildt J; Lisinen I; Ahonen A; Heiskanen I; Väisänen M; Arola J; Korsoff P; Ebeling T; Sane T; Minn H; Välimäki MJ; Nuutila P
    J Nucl Med; 2011 Dec; 52(12):1855-63. PubMed ID: 22052128
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Radioguided hepatic resection with
    López-Gómez J; Medina-Ornelas S; Salazar-Álvarez MA; Álvarez-Bojórquez M; Zaragoza-Cruz N; Melchor-Ruan J; Álvarez-Cano A
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2018; 37(4):244-249. PubMed ID: 29754940
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anti-carcinoembryonic antigen antibodies versus somatostatin analogs in the detection of metastatic medullary thyroid carcinoma: are carcinoembryonic antigen and somatostatin receptor expression prognostic factors?
    Behr TM; Gratz S; Markus PM; Dunn RM; Hüfner M; Schauer A; Fischer M; Munz DL; Becker H; Becker W
    Cancer; 1997 Dec; 80(12 Suppl):2436-57. PubMed ID: 9406695
    [TBL] [Abstract][Full Text] [Related]  

  • 32. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic implication of fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography in patients with recurrent papillary thyroid cancer.
    Kang JH; Jung DW; Pak KJ; Kim IJ; Kim HJ; Cho JK; Shin SC; Wang SG; Lee BJ
    Head Neck; 2018 Jan; 40(1):94-102. PubMed ID: 29130586
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Diagnosis of metastases from postoperative differentiated thyroid cancer: comparison between FDG and FLT PET/CT studies.
    Nakajo M; Nakajo M; Jinguji M; Tani A; Kajiya Y; Tanabe H; Fukukura Y; Nakabeppu Y; Koriyama C
    Radiology; 2013 Jun; 267(3):891-901. PubMed ID: 23468571
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of ⁶⁸Ga-DOTATATE PET-CT, ¹⁸F-FDG PET-CT and 99mTc-(V)DMSA scintigraphy in the detection of recurrent or metastatic medullary thyroid carcinoma.
    Ozkan ZG; Kuyumcu S; Uzum AK; Gecer MF; Ozel S; Aral F; Adalet I
    Nucl Med Commun; 2015 Mar; 36(3):242-50. PubMed ID: 25369749
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Role of 18F-FDG-PET and PET/CT imaging in thyroid cancer.
    Nanni C; Rubello D; Fanti S; Farsad M; Ambrosini V; Rampin L; Banti E; Carpi A; Muzzio P; Franchi R
    Biomed Pharmacother; 2006 Sep; 60(8):409-13. PubMed ID: 16891093
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High CEA levels in a case of resected colorectal cancer: delayed diagnosis of metachronous medullary thyroid cancer.
    Chen SW; Chen YK
    World J Surg Oncol; 2017 Dec; 15(1):230. PubMed ID: 29284496
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The role of
    Şahin OE; Uslu-Beşli L; Asa S; Sağer S; Sönmezoğlu K
    Hell J Nucl Med; 2020; 23(3):321-329. PubMed ID: 33367304
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 18F-FDG PET detection of lymph node metastases in medullary thyroid carcinoma.
    Szakáll S; Esik O; Bajzik G; Repa I; Dabasi G; Sinkovics I; Agoston P; Trón L
    J Nucl Med; 2002 Jan; 43(1):66-71. PubMed ID: 11801705
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography-guided management of suspected recurrent papillary thyroid carcinoma: long-term follow-up with tumour marker responses.
    Dennis K; Hay JH; Wilson DC
    Clin Oncol (R Coll Radiol); 2012 Dec; 24(10):e168-72. PubMed ID: 22944464
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.